
Nutrition isn't a side note anymore: IISc and Tufts team up to heal through food
"It is widely recognized that food choices and nutrition play a critical role in preventing, managing, and treating diseases, and continuous research and discovery optimises care," says Christina Economos, Dean of Tufts' Gerald J and Dorothy R Friedman School of Nutrition Science and Policy.'We envision a multifaceted and flexible approach to training that equips all emerging physician-scientists and health researchers with a strong foundation in nutrition science,' she adds.THE CENTRE THAT COULD CHANGE IT ALLAt the core of this partnership is the proposed Interdisciplinary Centre for Nutrition Science and Medicine (ICNSM), which will be housed at the upcoming Tata IISc Medical School. It will combine the strengths of both institutions -- Tufts' leadership in global nutrition policy and IISc's scientific rigour and tech expertise.'This partnership can provide a platform for discovering disruptive scientific, public health, and systems-level solutions that can catalyse innovative nutritional intervention strategies and policy changes,' says Govindan Rangarajan, Director of IISc.
The centre will focus on nutrition research across disciplines -- from cancer and cardiovascular disease to immunity, gut health, ageing, and AI-powered dietary tech. It will also look at cultural factors shaping diets, including India's diverse food traditions.FOOD AS MEDICINE, NOT AFTERTHOUGHTWhat's making this alliance especially urgent is the global health reality: most diseases today aren't from viruses or bacteria, but from how we live and eat.Obesity, hypertension, diabetes, and fatty liver disease are rising sharply in India. But paradoxically, child malnutrition and micronutrient deficiencies remain widespread.According to Dr Rangarajan, 'Every third child is stunted, and more than 50% of children under 5 years of age are anaemic.' At the same time, India is the global capital of diabetes with over 100 million diabetics and 136 million pre-diabetics.This dual burden -- undernutrition and overnutrition -- demands a more sophisticated, localised approach to food as medicine. The IISc–Tufts centre will tackle just that.advertisement'We anticipate research that will impact our understanding of the role of nutrition in areas like ageing, cancer, obesity, and infectious diseases,' adds Sunil Kumar.FIXING WHAT MEDICAL EDUCATION MISSEDOne key goal of the centre is curriculum change. Nutrition competencies will be woven into the training of physicians and researchers at IISc, creating a new generation of health professionals who treat food not as an afterthought, but a first-line tool.
'Physicians may graduate without the tools or confidence to advocate for or partner with dieticians,' says Economos. 'Medical training often emphasises drugs and surgery, rather than preventing and managing illness through diet. We see this as an area of opportunity.'The centre also plans joint PhD programmes, visiting scholars, and nutrition courses co-developed by Tufts' Friedman School and IISc.GUT FEELINGS AND OLD WISDOMInterestingly, the project doesn't dismiss traditional health systems. In fact, it plans to harmonise cutting-edge gut microbiome research with Ayurvedic concepts like 'food as medicine'.advertisement'We hope to co-develop nutritional aspects unique to Indian culture,' says Dr Rangarajan. 'Traditional knowledge systems will be incorporated where applicable.'This approach respects the unique challenges of food habits and health in India -- a country where rice, roti, fermented foods, fasting, and feast all play a role in how people eat.AI, SENSORS AND PERSONALISED CAREBeyond diets and doctors, this centre also aims to bring technology into nutrition. Sensors, AI, and tele-nutrition will play a big role -- especially in low-resource settings where access to specialists is limited.'Researchers are discovering new ways to monitor a person's health and provide actionable, individualised data in real time,' says Sunil Kumar. 'This is a promising area of investigation.'There's also a plan to develop a tele-nutrition system that delivers real-time nutrition insights to primary care workers -- a game-changer for rural and underserved communities.
BEYOND THE CLINIC: ACCESS, AFFORDABILITY, AND FOOD JUSTICEOf course, no amount of tech or research will matter if healthy food isn't accessible. That's why the partnership isn't just about calories or vitamins -- it's about systems.advertisement'In areas with high levels of poverty and poor access to healthy food, obesity, diabetes and other chronic diseases are much higher than average,' says Economos. 'By tackling food access and differentiated health burdens, we can improve outcomes.'This lens is especially relevant in India, where urban poor populations often rely on ultra-processed, low-nutrition food due to cost or convenience.By focusing on food affordability, cultural eating habits, and the economics of supply chains, the centre aims to reshape healthcare at a structural level -- not just the individual.THREE THINGS THIS PROJECT DOES:Builds a new centre at IISc focused on nutrition science and integrative medicineEquips future doctors with real-world nutrition trainingUses AI and tele-nutrition to expand access in low-resource areas
At the heart of it, this collaboration is based on a simple truth: what we eat doesn't just affect how we feel -- it determines how we live. And now, finally, science and medicine are catching up.advertisementAs Economos puts it, 'Nutrition plays a critical role in the prevention, management, and treatment of both communicable and non-communicable diseases. Ongoing research and discovery are essential to optimising care.'This time, the prescription might just begin at your plate.- Ends

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
22 minutes ago
- Business Standard
Dr Reddy's Q1 result: Net profit up 2%, revenue hits record ₹8,545 crore
Hyderabad-based pharma major Dr Reddy's Laboratories (DRL) posted a consolidated net profit of ₹1,417 crore in the first quarter of financial year 2026 (Q1 FY26), a 2 per cent rise from ₹1,392 crore a year ago. The company clocked its highest-ever quarterly revenue at ₹8,545 crore, up 11 per cent year-on-year (Y-o-Y) from ₹7,672 crore. The increase in profit and revenue was attributed to new product launches and price hikes during the quarter. Sequentially, revenue was flat, with a marginal 0.4 per cent rise, while net profit declined by 11 per cent. G V Prasad, co-chairman and managing director, DRL, said: 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio.' Dr Reddy's is planning a major global rollout of semaglutide beginning in 2026, targeting 87 countries—including India, Brazil, Canada, and Turkey—subject to local patent expiries. In countries without active patents, launches will begin earlier. In India and Brazil, where the patent expires in March 2026, the company is targeting Day 1 launches. Erez Israeli, chief executive officer, DRL, said: 'The semaglutide launch is very important to us. It reflects our focus on business development, resource optimisation, and cost alignment for future growth. While there are execution risks, I'm confident we'll overcome them and continue our growth trajectory. Our pipeline includes 26 peptide-based GLP-1 products, expected to launch over the next decade.' Despite ongoing litigation with Novo Nordisk in India regarding the validity of the semaglutide patent, Dr Reddy's does not anticipate any delays or disruptions to its commercialisation plans. The company expects significant topline contribution from semaglutide, citing growing global demand for GLP-1 therapies in diabetes and weight management. Priced lower than Novo's offering (₹17,000 per month), Dr Reddy's plans to use its integrated manufacturing to enhance accessibility. Semaglutide is the first of 26 GLP-1 peptide-based drugs the company plans to launch globally over the next decade, with timing based on regional IP clearance. Dr Reddy's has guided for capital expenditure of approximately ₹2,700 crore in FY26, with major investments toward expanding peptide and biosimilar capacity in line with product-specific requirements. Segment Performance Global Generics: Revenue stood at ₹8,060 crore, up 10 per cent Y-o-Y, supported by new launches and stable volumes. North America: Revenue was ₹3,412 crore, down 11 per cent Y-o-Y due to price erosion in key products like Lenalidomide. The company launched five new products and filed one ANDA with the USFDA. As of June 2025, 73 filings are pending, including 70 ANDAs (43 Para IVs, 22 with potential First-to-File status) and three NDAs. Europe: Revenue surged 142 per cent Y-o-Y to ₹1,274 crore, driven by the NRT acquisition. The NRT business contributed ₹670 crore. Germany reported ₹320 crore (up 13 per cent), the UK ₹170 crore (up 10 per cent), and the rest of Europe ₹120 crore (up 30 per cent). Growth was led by new launches and forex gains, partly offset by price erosion. Thirteen new products were launched. Emerging Markets: Revenue rose 18 per cent Y-o-Y to ₹1,404 crore. Russia contributed ₹710 crore (up 28 per cent), the Commonwealth of Independent States and Romania ₹200 crore (up 2 per cent), and the rest of world territories ₹500 crore (up 13 per cent). A total of 26 new products were launched across these regions. Pharmaceutical Services and Active Ingredients: Revenue rose 7 per cent Y-o-Y to ₹818 crore, supported by new API launches, forex gains, and pharmaceutical services expansion. The company filed 12 Drug Master Files globally during the quarter. The results were announced post market hours. Dr Reddy's shares rose 0.58 per cent, closing at ₹1,247.50 apiece on the BSE.
&w=3840&q=100)

Business Standard
22 minutes ago
- Business Standard
Natco Pharma to acquire 35.75% stake in Adcock Ingram for ₹2,000 cr
The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals Sanket Koul New Delhi In a bid to enter the African market, Natco Pharma on Wednesday announced that it has submitted a firm intention for a ZAR 4 billion (Rs 2,000 crore) cash offer to acquire a minority stake in South Africa-based drugmaker Adcock Ingram Holdings (AIHL). If approved, the Hyderabad-based company will hold a 35.75 per cent stake in Adcock Ingram by offering ZAR 75.00 ($4.271) per share to minority stakeholders. The deal gives Natco a gateway into South Africa, with AIHL holding a 10 per cent share of the private pharmaceutical market in the country. It is also the largest supplier of hospital and critical care products in South Africa. This transaction would consolidate Natco's existing 0.80 per cent stake, making it the second-largest shareholder in AIHL, behind the Bidvest Group, which holds the remaining 64.25 per cent. 'Post-transaction, Natco will consolidate 35.75 per cent of AIHL's net profits in Natco's financial results in accordance with its shareholding,' the company said in a regulatory filing. If the deal proceeds, Adcock Ingram will be delisted from the Johannesburg Stock Exchange (JSE) and will continue to operate as a private South African business. Rajeev Nannapaneni, chief executive officer and vice-chairman of Natco Pharma, said the proposed acquisition would help the company tap into new revenue streams and expand its presence in one of the largest and fastest-growing emerging markets. In return, AIHL is expected to leverage Natco's research and development capabilities, regulatory expertise, and global marketing network to support local leadership and expansion into new markets. 'AIHL will benefit from a partnership with a research-focused, innovative, and vertically integrated pharmaceutical company, and over time, South Africans will be beneficiaries of wider access to affordable medicines,' said Andrew Hall, chief executive officer, AIHL. Valued at an estimated ZAR 11 billion ($632 million), AIHL generated revenues of ZAR 9.6 billion ($536 million) for the financial year ending June 2024. Founded in 1890, the company operates across four segments—prescription, consumer, over-the-counter (OTC), and hospitals. It has a diverse product portfolio ranging from generic and branded formulations to critical-care hospital products, as well as consumer and home-care products. The announcement was made after market hours. On Wednesday, Natco Pharma's shares rose by 2.01 per cent, ending the day's trade at Rs 1,034.75 apiece on the Bombay Stock Exchange (BSE).


Hans India
2 hours ago
- Hans India
Dr. Reddy's Laboratories' net profit slumps 11 pc to Rs 14,09 crore sequentially in Q1
Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), down 11 per cent sequentially, the company said in an exchange filing on Wednesday. The company had reported a consolidated profit of Rs 1,587.3 crore in the preceding quarter (Q4 FY25). However, the profit of the Hyderabad-based firm saw a marginal jump of over a per cent on year-on-year (YoY) from Rs 1,392 crore in the same quarter a year ago, according to the filing. Meanwhile, Dr. Reddy's Labs revenue stood at Rs 8,545.2 crore in the quarter under review, up around Rs 40 crore sequentially from Rs 8,506 crore, and Rs 872.5 crore year-on-year (YoY) from Rs 7,672.7 crore. The pharmaceutical company saw a jump of Rs 153 crore in its total operating expenses this quarter QoQ, leading to a decline in its net profit. The company reported total operating expenses of Rs 3,115.2 crore in Q1 FY26 against Rs 2,961.6 crore in Q4 FY25. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market," said GV Prasad, Co-Chairman and MD. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad added. Meanwhile, the company has expanded partnership with Alvotech to co-develop, manufacture and co-commercialise pembrolizumab, a biosimilar candidate, this quarter, as per the filing. It has also launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies. The shares of the company closed in positive territory on Wednesday. The stock settled at Rs 1,248.0, up 0.65 per cent. Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad.